Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK2 | O00142 | 5/20 | 0.74 |
| ▸ | PYGM | P11217 | 3/20 | 0.66 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.56 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.56 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.56 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.56 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.51 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | TK1 | P04183 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27786493 | 1.00 | TK2 (0.74) | TK2PYGMSLC28A1SLC28A2SLC29A1 | |
| SCHEMBL13597474 | 1.00 | TK2 (0.74) | TK2PYGMSLC28A1SLC28A2SLC29A1 | |
| SCHEMBL13447935 | 1.00 | TK2 (0.74) | TK2PYGMSLC28A1SLC28A2SLC29A1 | |
| SCHEMBL13413052 | 1.00 | TK2 (0.74) | TK2PYGMSLC28A1SLC28A2SLC29A1 | |
| SCHEMBL1532596 | 1.00 | TK2 (0.74) | TK2PYGMSLC28A1SLC28A2SLC29A1 | |
| SCHEMBL1627679 | 1.00 | TK2 (0.74) | TK2PYGMSLC28A1SLC28A2SLC29A1 | |
| SCHEMBL23083301 | 1.00 | TK2 (0.74) | TK2PYGMSLC28A1SLC28A2SLC29A1 | |
| SCHEMBL13252708 | 1.00 | TK2 (0.74) | TK2PYGMSLC28A1SLC28A2SLC29A1 | |
| SCHEMBL2587226 | 1.00 | TK2 (0.74) | TK2PYGMSLC28A1SLC28A2SLC29A1 | |
| SCHEMBL7571099 | 1.00 | TK2 (0.74) | TK2PYGMSLC28A1SLC28A2SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250127774-A1 | COMPOUNDS FOR LABELLING NUCLEIC ACID AND USES THEREOF | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIV (CA) | 2025-04-24 | — | — | US | claimed |
| CN-119325467-A | Compounds for labeling nucleic acids and uses thereof | 皇家学习促进学会/麦吉尔大学 | 2025-01-17 | — | — | CN | claimed |
| EP-4476206-A1 | COMPOUNDS FOR LABELLING NUCLEIC ACID AND USES THEREOF | The Royal Institution for the Advancement of Learning / McGill University (CA) | 2024-12-18 | — | — | EP | claimed |
| WO-2023150867-A1 | COMPOUNDS FOR LABELLING NUCLEIC ACID AND USES THEREOF | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2023-08-17 | — | — | WO | claimed |
| JP-4651942-B2 | — | — | 2011-03-16 | — | — | JP | claimed |
| US-20100168052-A1 | Treatment of EBV and KHSV Infection and Associated Abnormal Cellular Proliferation | PHARMASSET, INC. (US) | 2010-07-01 | — | — | US | claimed |
| US-20070197462-A1 | Treatment of EBV and KHSV infection and associated abnormal cellular proliferation | PHARMASSET, INC. (US) | 2007-08-23 | — | — | US | claimed |
| EP-1569658-A4 | TREATMENT OF EBV AND KHSV INFECTION AND ASSOCIATED ABNORMAL CELLULAR PROLIFERATION | PHARMASSETT LTD (BB) | 2007-05-30 | — | — | EP | claimed |
| JP-2005528334-A | — | — | 2005-09-22 | — | — | JP | claimed |
| EP-1569658-A2 | TREATMENT OF EBV AND KHSV INFECTION AND ASSOCIATED ABNORMAL CELLULAR PROLIFERATION | Pharmassett Ltd. (BB) | 2005-09-07 | — | — | EP | claimed |
| US-20030176392-A1 | Administering 5-substituted uracil-nucleosides or its pharmaceutically acceptable salt or prodrug for therapy of infected with Epstein-Barr virus or Kaposi's sarcoma-associated herpes (\"KHSV\") | EMORY UNIVERSITY | 2003-09-18 | — | — | US | claimed |
| WO-2003053360-A2 | TREATMENT OF EBV AND KHSV INFECTION AND ASSOCIATED ABNORMAL CELLULAR PROLIFERATION | PHARMASSETT LTD. (BB) | 2003-07-03 | — | — | WO | claimed |
| EP-3760734-B1 | NUCLEIC ACID MODIFICATION AND IDENTIFICATION METHOD | IMBA INST MOLEKULARE BIOTECH (AT) | 2025-08-20 | — | — | EP | disclosed |
| US-20250127774-A1 | COMPOUNDS FOR LABELLING NUCLEIC ACID AND USES THEREOF | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIV (CA) | 2025-04-24 | — | — | US | disclosed |
| CN-119325467-A | Compounds for labeling nucleic acids and uses thereof | 皇家学习促进学会/麦吉尔大学 | 2025-01-17 | — | — | CN | disclosed |
| EP-4476206-A1 | COMPOUNDS FOR LABELLING NUCLEIC ACID AND USES THEREOF | The Royal Institution for the Advancement of Learning / McGill University (CA) | 2024-12-18 | — | — | EP | disclosed |
| EP-0702675-A1 | METHOD FOR PALLADIUM CATALYZED CARBON-CARBON COUPLING AND PRODUCTS | WASHINGTON STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1996-03-27 | — | — | EP | disclosed |
| EP-0702675-A4 | METHOD FOR PALLADIUM CATALYZED CARBON-CARBON COUPLING AND PRODUCTS | UNIV WASHINGTON (US) | 1996-02-02 | — | — | EP | disclosed |
| US-5428149-A | Reacting vinyl and aryl stannanes with 2'-deoxy-5-halo-uridine | WASHINGTON STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1995-06-27 | — | — | US | disclosed |
| WO-1994029279-A1 | METHOD FOR PALLADIUM CATALYZED CARBON-CARBON COUPLING AND PRODUCTS | WASHINGTON STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1994-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176392-A1 | Administering 5-substituted uracil-nucleosides or its pharmaceutically acceptable salt or prodrug for therapy of infected with Epstein-Barr virus or Kaposi's sarcoma-associated herpes (\"KHSV\") | UMPS, UNG, TYMP | TK2 90/4885PYGM 1497/4885SLC28A1 19/4885 |
| US-20070197462-A1 | Treatment of EBV and KHSV infection and associated abnormal cellular proliferation | UMPS, ENTPD5, TK1 | TK2 54/4885PYGM 2479/4885SLC28A1 33/4885 |
| US-20250127774-A1 | COMPOUNDS FOR LABELLING NUCLEIC ACID AND USES THEREOF | POLRMT, NSUN2, NSUN3 | TK2 56/4885PYGM 3534/4885SLC28A1 80/4885 |
| US-20100168052-A1 | Treatment of EBV and KHSV Infection and Associated Abnormal Cellular Proliferation | UMPS, ENTPD5, TK1 | TK2 54/4885PYGM 2479/4885SLC28A1 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.